Early changes of muscle insulin-like growth factor-1 and myostatin gene expression in gastric cancer patients

Muscle and Nerve

Volumn 48, Issue 3, 2013, Pages 387-392

  Bonetto, Andrea ^a,d   Penna, Fabio ^a   Aversa, Zaira ^b   Mercantini, Paolo ^c   Baccino, Francesco M ^a   Costelli, Paola ^a   Ziparo, Vincenzo ^c   Lucia, Simone ^b   Fanelli, Filippo Rossi ^b   Muscaritoli, Maurizio ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cachexia; Human cancer; IGF 1; Myostatin; Ubiquitin ligases

Indexed keywords

ATROGIN 1; MESSENGER RNA; MUSCLE RING FINGER 1 PROTEIN; MYOSTATIN; SOMATOMEDIN C;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE EXPRESSION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; MUSCLE BIOPSY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECTUS ABDOMINIS MUSCLE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STOMACH CANCER; WEIGHT REDUCTION;

CACHEXIA; HUMAN CANCER; IGF-1; MYOSTATIN; UBIQUITIN LIGASES;

AGED; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; MUSCLE PROTEINS; MUSCLES; MYOSTATIN; RNA, MESSENGER; SKP CULLIN F-BOX PROTEIN LIGASES; STATISTICS, NONPARAMETRIC; STOMACH NEOPLASMS; UBIQUITIN-PROTEIN LIGASES;

EID: 84883054399     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23798     Document Type: Article

References (34)

1. Argilés JM, Anker SD, Evans WJ, Morley JE, Fearon KC, Strasser F, et al. Consensus on cachexia definitions. J Am Med Dir Assoc 2010;11:229-230.
2. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12:489-495.
3. Muscaritoli M, Anker SD, Argilés J, Aversa Z, Bauer JM, Biolo G, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics." Clin Nutr 2010;29:154-159.
4. Florini JR, Samuel DS, Ewton DZ, Kirk C, Sklar RM. Stimulation of myogenic differentiation by a neuregulin, glial growth factor 2. Are neuregulins the long-sought muscle trophic factors secreted by nerves? J Biol Chem 1996;271:12699-12702.
5. Duan C, Ren H, Gao S. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins: roles in skeletal muscle growth and differentiation. Gen Com Endocrinol 2010;167:344-351.
6. Attard-Montalto SP, Camacho-Hübner C, Cotterill AM, D'Souza-Li L, Daley S, Bartlett K, et al. Changes in protein turnover, IGF-I and IGF binding proteins in children with cancer. Acta Paediatr 1998;87:54-60.
7. Costelli P, Muscaritoli M, Bossola M, Penna F, Reffo P, Bonetto A, et al. IGF-1 is downregulated in experimental cancer cachexia. Am J Physiol Regul Integr Comp Physiol 2006;291:R674-R683.
8. Fan J, Molina PE, Gelato MC, Lang CH. Differential tissue regulation of insulin-like growth factor-I content and binding proteins after endotoxin. Endocrinology 1994;134:1685-1692.
9. Lee SJ, McPherron AC. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA 2001;98:9306-9311.
10. McPherron AC, Lee SJ. Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci USA 1997;94:12457-12461.
11. Schuelke M, Wagner KR, Stolz LE, Hübner C, Riebel T, Kömen W, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 2004;350:2682-2688.
12. Tsuchida K, Nakatani M, Uezumi A, Murakami T, Cui X. Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer. Endocr J 2008;55:11-21.
13. Tsuchida K, Targeting myostatin for therapies against muscle-wasting disorders. Curr Opin Drug Discov Devel 2008;11:487-494.
14. Reisz-Porszasz S, Bhasin S, Artaza JN, Shen R, Sinha-Hikim I, Hogue A, et al. Lower skeletal muscle mass in male transgenic mice with muscle-specific overexpression of myostatin. Am J Physiol Endocrinol Metab 2003;285:E876-E888.
15. Bradley L, Yaworsky PJ, Walsh FS. Myostatin as a therapeutic target for musculoskeletal disease. Cell Mol Life Sci 2008;65:2119-2124.
16. Baumann AP, Ibebunjo C, Grasser WA, Paralkar VM. Myostatin expression in age and denervation-induced skeletal muscle atrophy. J Musculoskelet Neuronal Interact 2003;3:8-16.
17. Kirk S, Oldham J, Kambadur R, Sharma M, Dobbie P, Bass J. Myostatin regulation during skeletal muscle regeneration. J Cell Physiol 2000;184:356-363.
18. Bonetto A, Penna F, Minero VG, Reffo P, Bonelli G, Baccino FM, et al. Deacetylase inhibitors modulate the myostatin/follistatin axis without improving cachexia in tumor-bearing mice. Curr Cancer Drug Targets 2009;9:608-616.
19. Costelli P, Muscaritoli M, Bonetto A, Penna F, Reffo P, Bossola M, et al. Muscle myostatin signalling is enhanced in experimental cancer cachexia. Eur J Clin Invest 2008;38:531-538.
20. Benny Klimek ME, Aydogdu T, Link MJ, Pons M, Koniaris LG, Zimmers TA. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem Biophys Res Commun 2010;391:1548-1554.
21. Liu CM, Yang Z, Liu CW, Wang R, Tien P, Dale R, et al. Effect of RNA oligonucleotide targeting Foxo-1 on muscle growth in normal and cancer cachexia mice. Cancer Gene Ther 2007;14:945-952.
22. Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010;142:531-543.
23. Aversa Z, Bonetto A, Penna F, Costelli P, Di Rienzo G, Lacitignola A, et al. Changes in myostatin signaling in non-weight-losing cancer patients. Ann Surg Oncol 2012;19:1350-1356.
24. Lunetta C, Serafini M, Prelle A, Magni P, Dozio E, Ruscica M, et al. Impaired expression of insulin-like growth factor-1 system in skeletal muscle of amyotrophic lateral sclerosis patients. Muscle Nerve 2012;45:200-208.
25. Baumann AP, Ibebunjo C, Grasser WA, Paralkar VM. Myostatin expression in age and denervation-induced skeletal muscle atrophy. J Musculoskelet Neuronal Interact 2003;3:8-16.
26. Smith IJ, Aversa Z, Alamdari N, Petkova V, Hasselgren PO. Sepsis downregulates myostatin mRNA levels without altering myostatin protein levels in skeletal muscle. J Cell Biochem 2010;111:1059-1073.
27. Bossola M, Muscaritoli M, Costelli P, Grieco G, Bonelli G, Pacelli F, et al. Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann Surg 2003;237:384-389.
28. Smith IJ, Aversa Z, Hasselgren PO, Pacelli F, Rosa F, Doglietto GB, et al. Calpain activity is increased in skeletal muscle from gastric cancer patients with minimal or no weight loss. Muscle Nerve 2011;43:410-414.
29. Léger B, Senese R, Al-Khodairy AW, Dériaz O, Gobelet C, Giacobino JP, et al. Atrogin-1, MuRF1, and FoXO, as well as phosphorylated GSK-3beta and 4E-BP1 are reduced in skeletal muscle of chronic spinal cord-injured patients. Muscle Nerve 2009;40:69-79.
30. Khal J, Hine AV, Fearon KC, Dejong CH, Tisdale MJ. Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. Int J Biochem Cell Biol 2005;37:2196-2206.
31. Mastrocola R, Reffo P, Penna F, Tomasinelli CE, Boccuzzi G, Baccino FM, et al. Muscle wasting in diabetic and tumor-bearing rats: role of oxidative stress. Free Rad Biol Med 2008;44:584-593.
32. Dehoux M, van Beneden R, Pasko N, Lause P, Verniers J, Underwood L, et al. Role of the insulin-like growth factor I decline in the induction of atrogin-1/MAFbx during fasting and diabetes. Endocrinology 2004;145:4806-4812.
33. Fang CH, Li BG, James JH, King JK, Evenson AR, Warden GD, et al. Protein breakdown in muscle from burned rats is blocked by insulin-like growth factor 1 and glycogen synthase kinase-3beta inhibitors. Endocrinology 2005;146:3141-3149.
34. Attaix D, Baracos VE. MAFbx/Atrogin-1 expression is a poor index of muscle proteolysis. Curr Opin Clin Nutr Metab Care 2010;13:223-224.